Robert Milne

Welcome. I worked within the School of Pharmacy and Medical Sciences for many decades, but I have now retired from full-time employment. I have had many years of experience in teaching, research and consulting in pharmacy and pharmaceutical science. I have consulted widely to the pharmaceutical and biotechnology industry on pre-clinical and clinical studies, and worked closely with CPR Pharma, a spin-out company from UniSA. I have also provided scientific advice to patent firms on matters related to pharmaceutical science. I now work part-time with the Drug Discovery and Development group, which is within the Centre for Cancer Diagnostics and Therapeutics. My contribution is research and supervision of doctoral students, supporting pre-clinical evaluation of the pharmacology of new anti-cancer drugs. Drug discovery - preclinical development, pharmacokinetics and metabolism of drugs and their metabolites, drug analysis.

[2026] Safaroghli-Azar, A., Mekonnen, L. B., Lenjisa, J., Milne, R., & Wang, S. (2026). Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.. J Hematol Oncol, 19(1), 42 pages. [2025] Mekonnen, L. B., Teo, T., Noll, B., Rahaman, M. H., Lenjisa, J., Basnet, S., . . . Wang, S. (2025). A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189(118340), 118340.